Meacor is a start-up developing novel minimally invasive medical devices with a special focus on transcatheter interventions for valvular disease.

MeaCor is developing a novel medical device that aims at treating mitral valve regurgitation without open-heart surgery, a very serious heart condition that affects hundreds of thousands of patients in the world.

The start-up is a spinoff from Mcgill University and is currently in the product development phase with anticipated pre-clinical trials during the year 2016.

    Team Members

    Toufic Azar / CEO